 |
|
|
| |
Real-World Health Care Resource Utilization and Quality of Life With Glecaprevir/Pibrentasvir Treatment:
A Pooled Analysis From Post-Marketing Observational Studies
|
| |
| |
Reported by Jules Levin
AASLD/EASL HCV Special Conference, February 1-2, 2019, Miami, Florida, United States
Alessio Aghemo1, Stefan Bourgeois2, Michael Gschwantler3, Yuri Sanchez Gonzalez4, Lois Larsen4, Mark Bondin4, Rawi Hazzan5, Lorenzo Magenta6, Tarik Asselah7
1Humanitas University and Research Hospital, Rozzano, Italy; 2Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium; 3Department of Internal Medicine IV, Wilhelminenspital, and Sigmund Freud University, Vienna, Austria; 4AbbVie Inc., North Chicago, Illinois, United States; 5Emek Medical Center, Afula, Israel; 6Epatocentro Ticino, Lugano, Switzerland; 7Hopital Beaujon & INSERM UMR 1149, Clichy, France
|
| |
|
|
|
|
|
